433P - Efficacy and safety of bevacizumab (BV) and irinotecan (I) in elderly patients with recurrent glioblastoma multiform (GBM): A monocentric retrospec...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Geriatric Oncology
Central Nervous System Malignancies
Biological Therapy
Presenter Marie Robert
Citation Annals of Oncology (2014) 25 (suppl_4): iv137-iv145. 10.1093/annonc/mdu330
Authors M. Robert1, C. Leux2, C. Gourmelon1, M. Campone3, J. Frenel1
  • 1Centre René Gauducheau, Institut de Cancérologie de l'Ouest, FR-44805 - St Herblain CEDEX/FR
  • 2Phu Santé Publique Et Santé Au Travail, Centre Hospitalier Universitaire de Nantes, 44093 - Nantes/FR
  • 3Medical Oncology, Institut de Cancérologie de l’Ouest - René Gauducheau, Herblain/FR



The combination of BV + I is an option for the treatment of recurrent GBM. However, its use in elderly patients remains controversial.


We retrospectively reviewed the medical records of all the patients who received BV + I for recurrent GBM in our institution. GBM histology/grade IV astrocytoma progressing after concurrent radiotherapy with temozolomide were retrieved. Toxicity, overall survival (OS) and progression free survival (PFS) were compared between patients < 65 and ≥ 65 years old.


From 2007 to 2013, 84 patients were included (Male 52/Female32), reparted in < 65 years old (group A), n= 54 and ≥ 65 years old (group B), n = 30. Performans status at relapse was 0-1 (n = 50) or >2 (n = 23). The most frequent grade 3-4 adverse events were veinous thromboembolic events (6 in the group A vs 1 in the group B) and asthenia (3 vs 2). Hypertension and asthenia were more reported in elderly patients: 20% vs 3,7% (HR 6,5; 95%CI : 1,22-34,59, p = 0,028) and 76,7% vs 48,1% (HR 3,54; 95%CI : 1,3-9,62; p = 0,013) respectively. Patient >65y had a similar PFS and OS with B + I than those <65y: median PFS were respectively 7.1 months (95%CI, 6.0-8.8) versus 6.2 months (95%CI, 5.4-7.5) and median OS 8.5 months (95%CI, 7.1-13.5) versus 8.9 months (95%CI, 7.3-11.0).


In this study, BV + I in >65y patients is as effective and safe as in <65y patients.


All authors have declared no conflicts of interest.